Advertisement
Screener

AIM IMMUNOTECH INC. (AIM) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances

2.8 / 5 stars · 68/120 Roast Me

AIM IMMUNOTECH INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances

AIM IMMUNOTECH INC. (AIM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $1.49 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-14.

Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2018-11-14

  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2017-12-31 was -$24.00K.
  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2017-09-30 was $84.00K.
  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2017-06-30 was $1.27M.
  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2017 was $2.05M, a 21.67% decline from fiscal 2016.
  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2016 was $2.62M.
  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2014 was -$14.00K.
Period endFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 3 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 6 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 9 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month
2018-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14
$1.49M
10-Q · filed 2018-11-14
2018-06-30$1.49M
10-Q · filed 2018-08-14
2017-12-31-$24.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30
$60.00K
derived: sum of 2 quarters · filed 2018-03-30
$1.33M
derived: sum of 3 quarters · filed 2018-03-30
$2.05M
10-K · filed 2018-03-30
2017-09-30$84.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14
$1.35M
derived: sum of 2 quarters · filed 2017-11-14
$2.07M
10-Q · filed 2017-11-14
$2.07M
derived: sum of 4 quarters · filed 2017-11-14
2017-06-30$1.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14
$1.99M
10-Q · filed 2017-08-14
$1.99M
derived: sum of 3 quarters · filed 2017-08-14
2017-03-31$723.00K
10-Q · filed 2017-05-15
$723.00K
derived: sum of 2 quarters · filed 2017-05-15
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31
$2.62M
10-K · filed 2017-03-31
2016-09-30$2.62M
10-Q · filed 2016-11-14
2014-12-31-$14.00K
10-K · filed 2017-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
CURIS INC (CRIS)United States$0.002B-0.05
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Silexion Therapeutics Corp (SLXN)$0.001B